US3608080A - Process for the treatment of hyperuremia of nephritis - Google Patents

Process for the treatment of hyperuremia of nephritis Download PDF

Info

Publication number
US3608080A
US3608080A US713802A US71380268A US3608080A US 3608080 A US3608080 A US 3608080A US 713802 A US713802 A US 713802A US 71380268 A US71380268 A US 71380268A US 3608080 A US3608080 A US 3608080A
Authority
US
United States
Prior art keywords
treatment
acid
sua
sarcosyluric
uricemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US713802A
Other languages
English (en)
Inventor
Francis Albert Kirsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of US3608080A publication Critical patent/US3608080A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Definitions

  • Sarcosyluric acid is known chemical compound the therapeutical properties of which had not been evidenced heretofore.
  • Mylius It was described, in particular, by Mylius (Ber. 1884, 17, 517) under the name of sarcosinuric acid. Mylius described also a process for the preparation of this compound, comprising reacting uric acid with excess sarcosine above the melting point (2 l 2 C.) of the latter.
  • Sarcosyluric acid has the following physical-chemical properties:
  • Sarcosyluric acid is more water-soluble than uric acid, in an amount of about 17 g./liter at 20 C. Solubility increases considerably at alkaline pH values.
  • An ammonium salt is readily prepared by dissolution in dilute ammonia solution followed by concentration in vacuo. This salt and similar salts may also be used, just as sarcosyluric acid, as active principle of the therapeutical composition according to the present invention.
  • the UV spectrum of sarcosyluric acid determined in water shows a strong shift of the bands present in the spectrum of uric acid. This shift may correspond to a suppression of the resonance effects caused by the introduction of sarcosine.
  • uric acid shows three bands at 203,233 and 287 mu with a shoulder at about 295 my; sarcosyluric acid shows three bands at 200, 216 and 259 mp with a shoulder at 265 2.
  • the IR spectrum was determined with a suspension in pure paraffin oil. It possesses a highly complex set of bands. It-
  • the mass spectrum determined using a ms9 apparatus at 280 shows the expected molecular ion at m./e. 239, together with an abundant ion at m./e. 168 due to the loss of (M 71). By its mass, the ion at 168 corresponds to uric acid.
  • the mass spectrographic behavior of sarcosyluric acid is consistent with the contemplated structure of a fixation of sarcosine by the carboxyl.
  • the weight curve of the treated animals is found to be identical with that of the controls.
  • the weight curve of the treated animals is:
  • the weight gain is slightly higher than that of the controls, from the 7th week on, and until the end of the treatment.
  • EXPERIMENTAL PROCEDURE Two reference female rabbits having an average weight of 3 kg. were given intravenously l ml./kg. of a aqueous arginine hydrochloride solution (i.e., I g./kg. of arginine hydrochloride). Blood samples were taken: 5 minutes prior to injection of arginine, than 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours and 24 hours after injection. Serum urea determination was carried out with each sample using a specific micromethod involving urease.
  • FIG. 1 illustrates such results by means of a graph showing the percent increase of the urea level as a function of time.
  • Curve A relates to the controls who were given only I g./kg. (i.v.) of arginine;
  • curve B relates to the animals given I00 mg./kg. of sarcosyluric acid orally 30 minutes prior to the administration of argininc;
  • curve C relates to the animals given I00 mg./kg. orally, one hour prior to the administration of arginine, and curve D relates to the animals given 100 mg./kg. orally, 24 hours prior to the administration of arginine.
  • composition according to the invention may be used:
  • sarcosyluric acid may be associated with an anti-inflammatory drug such as aspirin or phenyl butazone.
  • the drug may be administered by the oral, parenteral and rectal routes, the active principle being associated with the vehicles and excipients suitable for such various routes of administration.
  • suitable although nonlimiting pharmaceutical forms are tablets, perfusion vials and suppositories.
  • uricuria 875 mg. per day. After SUA: uricemia 90 and I00 mg. p.l.
  • uricuria 540 mg./24 hrs. CASE REPORT 3 Mr. DAV... F., 45 years old. First attack at the age of42. No tophus. Treated for gouty polyarthritis with COLCHICINE 2 mg. per day. Is given 4 tablets daily of SUA, during 1 week, while continuing to take COLCHICINE.
  • uricuria 380 and 640 mg./day After SUA: uricemia 52 rng./l.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US713802A 1967-03-20 1968-03-18 Process for the treatment of hyperuremia of nephritis Expired - Lifetime US3608080A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR99444A FR6142M (fr) 1967-03-20 1967-03-20 Médicament à base d'acido sarcosylurique.

Publications (1)

Publication Number Publication Date
US3608080A true US3608080A (en) 1971-09-21

Family

ID=8627197

Family Applications (1)

Application Number Title Priority Date Filing Date
US713802A Expired - Lifetime US3608080A (en) 1967-03-20 1968-03-18 Process for the treatment of hyperuremia of nephritis

Country Status (2)

Country Link
US (1) US3608080A (fr)
FR (2) FR6142M (fr)

Also Published As

Publication number Publication date
FR283F (fr) 1969-11-03
FR6142M (fr) 1968-08-01

Similar Documents

Publication Publication Date Title
US4228099A (en) Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
EP0491708B1 (fr) Separation d'aminoarginine, utilisee pour bloquer la formation d'oxyde nitrique dans le corps
US4320146A (en) Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4749707A (en) Citric acid salt of (+) vinpocetine
DE2711493A1 (de) Substanzen zur behandlung von arthritis
TW200838545A (en) Therapeutic agent for painful disease
JPS5843996A (ja) 安定なｓ−アデノシルメチオニン塩、それらの製造法及び活性成分としてこれらを含む治療組成物
EP2249821A1 (fr) Utilisation d'esters d'acide amidoxime-carboxylique et d'esters d'acide n-hydroxyguanidine-carboxylique pour la fabrication de promédicaments
DE69029732T2 (de) Bivalente metallsalze von indomethacin
KR0151389B1 (ko) 신질환치료제
JPS59205347A (ja) 新規な２−〔（２，６−ジクロロフエニル）アミノ〕フエニルアセトキシアセチル誘導体、その製造法およびその治療用組成物
AU2020341121B2 (en) Compounds comprising curcumin and basic amino acids
CH664561A5 (it) Estere dell'acetil carnitina, procedimento per la sua preparazione e composizioni farmaceutiche che lo contengono.
US3608080A (en) Process for the treatment of hyperuremia of nephritis
EP0177356A2 (fr) Méthode de traitement de l'antidiurèse
JPS62190190A (ja) Ｌ−カルニチンのホスホリルアルカノ−ルアミド誘導体類およびその医薬組成物
JPS6131118B2 (fr)
US6197818B1 (en) Drug for treating diabetic nephrosis
EP0990441A1 (fr) Medicament pour le traitement de la nephropathie diabetique
US3062719A (en) Trisodium calcium diethylenetriaminepentaacetic acid, compositions containing the same, and the use thereof
CN114349665A (zh) 二甲双胍焦谷氨酸晶体及其制备方法与应用
RU2045268C1 (ru) Противогистаминное и антиаллергическое средство и способ приготовления глутамината хинуклидил-3-дифенилкарбинола в виде раствора для инъекций
RU2233661C1 (ru) Селенотерпенопротеиновое органическое вещество, обладающее биологически активным действием
US3461211A (en) Lipotropic compositions and their administration
LU81745A1 (fr) N-(1-methyl-2-pyrrolidinyl methyl)-2,3-dimethoxy 5-methyl-sulfamoyl benzamide et ses derives,leurs methodes de preparation et leur application dans le traitement des troubles du bas appareil urinaire